Cardiotoxicity ScreeningIn vitro Toxicology
• hERG Predictor fluorescence polarisation assay (Invitrogen)
Cardiotoxicity is one of the main reasons for safety-related compound attrition and drug withdrawals, and therefore should be screened in the early stages of drug discovery. The laborious and expensive traditional patch-clamp assay for measuring hERG blockage (an indicator for cardiotoxicity) is not a practical assay for screening. That is why we offer a more cost-efficient screening tool for evaluating cardiotoxicity as a part of our toxicity screening portfolio.
Our rapid hERG Predictor fluorescence polarisation assay is used for screening of compounds acting as potential ligands or blockers of hERG channel. The assay utilises 384-well plate format and delivers IC50 values towards hERG blockage in relation to a well-known hERG ligand, E-4031 as well as negative controls.